StemCells, Inc. (NASDAQ:STEM)

CAPS Rating: 2 out of 5

A biopharmaceutical company that operates in one segment, the development of novel cell-based therapeutics designed to treat human diseases and disorders.

Recs

0
Player Avatar mjbizdev (< 20) Submitted: 11/11/2012 7:40:16 AM : Underperform Start Price: $1.76 STEM Score: +64.51

This name repersents the amplification of near term collection of "false hopes" IMHO. I think investors will be dissapointed and dissillusioned in a significant way. I'd like to short this on weakness and buy after exhaustion selling over and over again. Just not in my focus to track.

Featured Broker Partners


Advertisement